Autopsy report · NCT02983097

Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP

“Phase II: no scientific interests are given anymore”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 years after it had already started.
• Ran for about 4 years 5 months before it stopped.
• 34 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH

Sponsor type

University, hospital or other

Conditions

Diffuse Large B-cell Lymphoma (DLBCL); Follicular Lymphoma Grade III (FL III°); Mantle Cell Lymphoma (MCL), Blastoid Variant; Burkitt Lymphoma (BL); Aggressive Marginal Zone Lymphoma (MZL)

Interventions

Rituximab; Cisplatin; Carboplatin; Dexamethasone; Cytarabine; Lenalidomide

Participants

34

Sites

12

Countries

Germany

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.